Managing severe infection in infancy in resource poor settings  by Seale, Anna C. & Berkley, James A.
Early Human Development 88 (2012) 957–960
Contents lists available at SciVerse ScienceDirect
Early Human Development
j ourna l homepage: www.e lsev ie r .com/ locate /ear lhumdevManaging severe infection in infancy in resource poor settings
Anna C. Seale ⁎, James A. Berkley
KEMRI-Wellcome Centre for Geographic Medicine and Research — Coast, PO BOX 230, Kiliﬁ 80108, Kenya
Centre for Clinical Vaccinology and Tropical Medicine, Oxford University, Churchill Hospital, Oxford OX3 7LE, UK⁎ Corresponding author at: Centre for Clinical Vaccin
Oxford University, Churchill Hospital, Oxford OX3 7LE
E-mail addresses: aseale@kemri-wellcome.org (A.C.
jberkley@kemri-wellcome.org (J.A. Berkley).
0378-3782 © 2012 Elsevier Ireland Ltd.
http://dx.doi.org/10.1016/j.earlhumdev.2012.09.005
Open access undera b s t r a c ta r t i c l e i n f oKeywords:
Infant
Neonatal
Newborn
Infection
Management
Resource-poorReducing childhoodmortality in resource-poor regions depends on effective interventions to decrease neona-
tal mortality from severe infection, which contributes up to a half of all neonatal deaths. There are key differ-
ences in resource-poor, compared to resource-rich, countries in terms of diagnosis, supportive care and
treatment. In resource-poor settings, diagnosis is based on identifying clinical syndromes from international
guidelines; microbiological investigations are restricted to a few research facilities. Low levels of stafﬁng
and equipment limit the provision of basic supportive care, andmost facilities cannot provide respiratory sup-
port. Empiric antibiotic treatment guidelines are based on few aetiological and antimicrobial susceptibility
data. Research on improving health care systems to provide effective supportive care, and implementation
of simple pragmatic interventions, such as low-cost respiratory support, are essential, together with improved
surveillance to monitor emerging drug resistance and treatment failures. Reductions in mortality will also be
achieved through prevention of infection; including emerging vaccination and anti-sepsis strategies.
© 2012 Elsevier Ireland Ltd. Open access under CC BY license.1. Introduction
Whilst substantial progress has been made in reducing childhood
mortality in the under 5s in resource-poor regions, progress in reducing
deaths in the neonatal period (b28 days), has been limited. Globally,
under-5 mortality has declined by 28%, from 90 deaths per 1000 live
births in 1990, to 65 in 2008 [1]. Reductions in neonatal mortality
have, however, been considerably less, and are slowest in regions
with the highest burden, South-east Asia and Africa; Africa's neonatal
mortality only decreased 17.6% (43.6 to 35.9 per 1000 live births) be-
tween 1990 and 2009 [2]. Thus there is an epidemiological transition
in childhood mortality, with neonates representing an increasing pro-
portion (41%) of the global burden of childhood deaths [3]. In order to
make further progress towards Millennium Development Goal 4 of re-
ducing childhoodmortality by two thirds between 1990 and 2015, neo-
natal mortality must be reduced.
Here we aim to provide an overview of some of the key differences
in management of severe infection in resource-poor compared to
resource-rich settings, and consider research directions to improve
management and to prevent infection. We restrict this paper to
severe bacterial infection since there are limited data on congenital
infections such as cytomegalovirus and rubella in resource-poor set-
tings, but these are important areas for future research.ology and Tropical Medicine,
, UK. Tel.: +254 41 522535.
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The principle causes of neonatal mortality are infection, birth as-
phyxia and preterm birth. In resource-poor settings, infection likely
contributes to up to a half of all neonatal deaths [4]. This is due to a
high burden of infectious disease, but also high levels of co-morbidity
including intrauterine growth restriction (IUGR) and preterm birth:
85% of all preterm births occur in Africa and Asia [5]. In one study in
rural India, combinations of preterm birth and sepsis, and IUGR and
sepsis, resulted in 35% and 22.5% of neonatal deaths respectively [6].
Maternal HIV infection is also associated with neonatal mortality in
resource-poor settings [7]; in both HIV exposed uninfected (HEU) and
HIV exposed infected (HEI) infants [8]. This may be in part due to
lower speciﬁc antibody responses, associatedwith ante-natal HIV expo-
sure [9]. However, recent data suggest that it is HEI neonates that are
most at risk. Secondary analysis of an anti-sepsis trial in South Africa
[10] reportedmuch higher rates in HEI than HEU infants of both neona-
tal early onset sepsis (EOS) (134 vs 21.5 per 1000; Pb0.0001) and late
onset sepsis (LOS) (26.8 vs 5.6 per 1000; P=0.042) [11].
3. Diagnosis
In resource-poor settings, most sick newborns are not assessed
and managed by specialist paediatricians. Clinicians are usually de-
pendent on recognition of patterns of clinical signs and symptoms
for diagnosis, which is central to management (illustrated in Fig. 1).
Algorithms such as those given in the World Health Organisation
(WHO) Integrated Management of Childhood Illness (IMCI) support
this approach, together with courses providing training in Emergency
Fig. 1. Contributors to optimising management of severe infection in neonates in resource poor-settings.
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pragmatic approach to detect severe illness with an appropriate
index of clinical suspicion; features normally obtained in a history
in resource-rich settings, such as maternal pyrexia, prolonged rupture
of membranes, and gestation may be unknown. Basic laboratory
investigations to support diagnosis, such as C-reactive protein and a
full blood count may be unavailable. Most hospitals lack microbiolog-
ical facilities to detect invasive infection (primarily blood or cerebro-
spinal ﬂuid cultures) and high quality microbiological investigations
are almost always restricted to a few research settings [12].
Identifying the best clinical predictors of severe disease in young
infants in resource-poor settings is therefore essential to developing
effective guidelines. In the ﬁrst WHO multinational study of severe
bacterial infection in young infants conducted in Ethiopia, The Gambia,
The Philippines and Papua New Guinea [13], fourteen clinical signs
and symptoms were identiﬁed as key predictors of severe disease
[14]. However, the study was limited in terms of identifying early neo-
natal infection, by the number of neonates in the ﬁrst week of life
included in the study. A more recent, larger WHO multinational study
in Bangladesh, Bolivia, Ghana, India, Pakistan, and SouthAfrica recruited
3177 neonates aged 0–6 days and 5712 infants aged 7–59 days. It
identiﬁed seven factors in neonates aged 0–6 days (severe jaundice
excluded), of which the presence of one predicted severe illness, with
high sensitivity (85%) and speciﬁcity (75%). These were: history of
difﬁculty feeding, history of convulsions, movement only when stimu-
lated, respiratory rate≥60 breaths per minute, severe chest indrawing,
and temperature >37.5 °C or b35.5 °C. These indicators had similar
sensitivity (74%) and speciﬁcity (79%) in 7–59 day old infants [15].
There are limitations to the use of clinical signs and symptoms for
diagnosis of severe infection. Absence of microbiological culture in-
vestigation limits individual management; physicians are unable to
rationalise and direct antibiotic treatment, and conﬁrm their clinical
diagnoses and there are particular difﬁculties in conﬁrming the diag-
nosis of neonatal meningitis, for which signs and symptoms are
non-speciﬁc. Lumbar puncture is an important diagnostic tool for
neonatal meningitis, and can provide useful information even with-
out the availability of microbiological culture [16]. New diagnostic
methods which are low complexity and not reliant on conventionalculture could make microbiological diagnosis more affordable and
feasible in resource-poor settings. They are easily performed, not re-
quiring highly trained, qualiﬁed laboratory staff. Examples include
rapid immunochromatographic tests, such as those for Streptococcus
pyogenes (Group A Streptococcus) [17], as well as HIV and malaria.
Rapid tests using PCR based methods are also in development.
4. Supportive care
Resource-poor settings are limited in their ability to provide basic
supportive care (including routine observation, monitoring and docu-
mentation) by inadequate stafﬁng (for example 2 trained staff to 100
children is not uncommon), as well as availability of training and
equipment. Routine newborn documentation can be inadequate for
care. Although simple admission pro forma, such as newborn admis-
sion records, can help improve clinical assessment and record keeping
[18] improving overall supportive care is challenging and requires
strengthening of health systems. A recent cluster randomised trial in
eight rural Kenyan hospitals reported that changing practice is best
achieved through comprehensive intervention, including evidence-
based guidelines, training, job aides, local facilitation, supervision,
and face-to-face feedback; when compared to a smaller intervention
package of guidelines, didactic training, job aides, and written feed-
back. Completion of admission assessment tasks was higher in the
comprehensive intervention sites at 18 months compared to partial
(mean=0.94 versus 0.65) [19].
Where neonatal care is limited, alternatives to conventional care
may be appropriate and beneﬁcial. Kangaroo mother care has been
shown to reduce neonatal infection at 40–41 weeks gestational age
(typical RR 0.42, 95% CI 0.24 to 0.73 from meta-analysis) in stabilised
low birth weight neonates, but more work is needed to establish its
use in neonates requiring more conventional neonatal support [20].
A speciﬁc and important element of neonatal supportive care, lack-
ing in resource-poor settings, is respiratory support. This is due to de-
ﬁciencies in equipment, and a lack of training for health care staff.
There are, however, methods of providingmild tomoderate respirato-
ry support through continuous positive airway pressure (CPAP)which
are potentially more feasible and low-cost for use in resource-poor
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ventilation [21]. Bubble-CPAP is a variation of conventional CPAP in
which gas ﬂows through the expiratory CPAP tubing, submerged un-
derwater to a depth equal to the required positive end expiratory
pressure (PEEP) in centimetres. This is an intervention that appears
to have great potential, but it is important that bubble-CPAP is used
safely in resource poor settings [22], with appropriate training and
monitoring, as recently demonstrated in studies in Malawi and Fiji
[23,24].
5. Antimicrobial treatment
Developing appropriate treatment guidelines and evaluating their
efﬁcacy is challenging in resource-poor settings. In particular this re-
lates to the lack of microbiological investigation, which means data
on aetiology of neonatal infection and antibiotic sensitivities are
scarce. International guidelines from the World Health Organisation,
(WHO) Pocketbook of hospital care for Children, in common with
guidelines in resource-rich settings, recommend broad-spectrum par-
enteral antibiotics, usually a combination of penicillin and gentami-
cin, or a third generation cephalosporin, based on covering common
neonatal pathogens.
There are important differences in aetiology of neonatal infection in
resource-poor and resource-rich settings however. In resource-rich set-
tings, the leading causes of early onset neonatal sepsis (EOS (0–48 h))
are Escherichia coli and Streptococcus agalactiae (Group B Streptococcus,
GBS). GBS has only recently been identiﬁed as a pathogen in EOS in
resource-poor settings [25]. Listeriamonocytogenes is very rarely identi-
ﬁed in EOS in resource-poor settings [26], probably due to lower intake
of dairy foods than in resource-rich settings. Gram negative infections
(in addition to E. coli) such as Klebsiella pneumoniae, are more common
in resource-poor settings. In late onset sepsis (LOS (48 h–28 days)) a
key difference is the high incidence of coagulase negative Staphylococci
(CONS) in resource-rich settings. This usually occurs in preterm neo-
nates, associated with indwelling devices, such as percutaneous long
lines. In resource-poor settings it is unclear whether it is a contaminant,
or a pathogen, and the indwelling devices it is associatedwith aremuch
less commonly used. There are similarities in aetiology too, however, as
in both settings LOS is commonly caused by gram negative bacteria,
Staphylococcus aureus and Streptococcus pneumoniae [26,27].
Assessment of continued efﬁcacy of treatment guidelines is essen-
tial. In common with resource-rich settings, neonates in resource-poor
settings are at increasingly high risk of hospital acquired infection and
drug-resistant pathogens [28,29].Microbiological surveillance of patho-
gens and their antibiotic susceptibilities in resource-poor settings
should be a priority, as well as monitoring of treatment failures using
current guidelines.
Improving neonatal care in the community is also important be-
cause of difﬁculties accessing health services in some areas. A large
cluster randomised trial (39 intervention and 47 control villages) of
a package of home-based neonatal care in rural India, including com-
munity treatment of neonatal sepsis, decreased neonatal sepsis case
fatality from 16.2 to 2.8% [30].
6. Research directions
Research to improve diagnostic methods, pragmatic interventions
for supportive care and surveillance of drug-resistance for treatment
of neonatal infection in resource-poor settings are high priorities, as
described. However, research to prevent severe infection is also im-
portant, as discussed below.
Design and implementation of immunisation is a key element of
prevention and could build on and strengthen existing maternal
immunisation programmes (such as maternal tetanus) in resource-
poor settings. Potential vaccine candidates for neonatal sepsis include
Group B Streptococcus (GBS), for which a trivalent conjugate vaccineis in phase II clinical trials in pregnant women in South Africa [31].
Data on invasive serotypes of GBS in resource-poor settings are very
limited, andmore data are needed to inform vaccine development. Cur-
rent evidence suggests a ﬁve-valent vaccine (serotypes Ia, Ib, II, III, V)
would cover most GBS disease [25]. Future directions include new re-
search techniques using whole genome sequencing, which are increas-
ing the likelihood of successful identiﬁcation of new protein targets for
vaccines, for both GBS and other important neonatal pathogens such as
E coli [32].
Antisepsis is another strategy, however vaginal chlorhexidine was
shown to be ineffective before delivery in reducing neonatal sepsis in
a randomised controlled trial of 8011 women in South Africa [10]. In
contrast, anti-sepsis after delivery, at potential portals of infection,
such as the umbilical cord, represents a potentially highly effective
method of reducing neonatal infection. A factorial, cluster-randomised
trial in rural Pakistan, used 4% chlorhexidine solution applied to the
cord from birth to 14 days. There were reductions in omphalitis (risk
ratio 0.58, 95% CI 0.41–0.82) and neonatal mortality (risk ratio 0.62,
95% CI 0.45–0.85) in those with the chlorhexidine intervention,
although hand-washing (another arm of the trial) did not show any ef-
fect [33]. In addition, prevention of infection through protection of sites
of infection entry has also been demonstrated using skin emollients in
preterm neonates. Application of sunﬂower seed oil or Aquaphor oint-
ment in a randomised control trial of 497 neonates in Bangladesh,
resulted in 26% and 32% reductions in neonatal mortality rates com-
pared to no emollient therapy [34].
7. Conclusions
Improving management of severe infection in infancy is an interna-
tional priority. Key factors in improving care in resource-poor settings
are improved aetiological diagnosis and effective provision of support-
ive care, including non-invasive respiratory support. Effective preven-
tion strategies through new vaccines and anti-sepsis interventions are
important research directions.
Conﬂict of interest
None.
Acknowledgements
We thank Dr Susan Morpeth for her comments on the manuscript.
We also thank and acknowledge the support of the KEMRI-Wellcome
Trust Programme and this paper is published with the approval of the
director. Dr Anna Seale and Dr James Berkley are funded by the
Wellcome Trust (grant numbers WT093804MA and WT083579MA).
References
[1] You D, Wardlaw T, Salama P, Jones G. Levels and trends in under-5 mortality,
1990–2008. Lancet 2010;375(9709):100-3.
[2] Oestergaard MZ, Inoue M, Yoshida S, Mahanani WR, Gore FM, Cousens S, et al. Neo-
natal mortality levels for 193 countries in 2009 with trends since 1990: a systematic
analysis of progress, projections, and priorities. PLoS Med 2011;8(8):e1001080.
[3] Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, re-
gional, and national causes of child mortality in 2008: a systematic analysis. Lan-
cet 2010;375(9730):1969-87.
[4] Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? where? why? Lancet
2005;365:891-900.
[5] Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, et al. The worldwide
incidence of preterm birth: a systematic review of maternal mortality and mor-
bidity. Bull World Health Organ 2010;88(1):31-8.
[6] Bang AT, Reddy HM, Bang RA, Deshmukh MD. Why do neonates die in rural
Gadchiroli, India? (Part II): estimating population attributable risks and contribution
of multiple morbidities for identifying a strategy to prevent deaths. J Perinatol
2005;25(Suppl. 1):S35-43.
[7] Chilongozi D, Wang L, Brown L, Taha T, Valentine M, Emel L, et al. Morbidity and
mortality among a cohort of human immunodeﬁciency virus type 1-infected and
uninfected pregnant women and their infants from Malawi, Zambia, and Tanza-
nia. Pediatr Infect Dis J 2008;27(9):808-14.
960 A.C. Seale, J.A. Berkley / Early Human Development 88 (2012) 957–960[8] Koyanagi A, Humphrey JH, Ntozini R, Nathoo K, Moulton LH, Iliff P, et al. Morbidity
among human immunodeﬁciency virus-exposed but uninfected, human immuno-
deﬁciency virus-infected, and human immunodeﬁciency virus-unexposed infants
in Zimbabwe before availability of highly active antiretroviral therapy. Pediatr Infect
Dis J 2011;30(1):45-51.
[9] Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV
infection and antibody responses against vaccine-preventable diseases in uninfected
infants. JAMA 2011;305(6):576-84.
[10] Cutland CL, Madhi SA, Zell ER, Kuwanda L, Laque M, Groome M, et al. Chlorhexi-
dine maternal-vaginal and neonate body wipes in sepsis and vertical transmission
of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet
2009;374(9705):1909-16.
[11] Cutland CL, Schrag SJ, Zell ER, Kuwanda L, Buchmann E, Velaphi SC, et al. Maternal
HIV infection and vertical transmission of pathogenic bacteria. Pediatrics 2012;130:
1–10.
[12] Seale A, Mwaniki M, Newton CR, Berkley JA. Maternal and early onset neonatal
bacterial sepsis: burden and strategies for prevention in sub-Saharan Africa. Lancet
Infect Dis 2009;9(7):428-38.
[13] The WHO Young Infants Study Group. Bacterial etiology of serious infections in
young infants in developing countries: results of a multicentre study. Pediatr
Infect Dis J 1999;18(10 Suppl.):S17-22.
[14] WeberMW, Carlin JB, Gatchalian S, LehmannD,Muhe L,Mulholland EK. Predictors of
neonatal sepsis in developing countries. Pediatr Infect Dis J 2003;22(8):711-7.
[15] Young Infants Clinical Signs Study Group. Clinical signs that predict severe illness
in children under age 2 months: a multicentre study. Lancet 2008;371(9607):
135-42.
[16] Mwaniki MK, Talbert AW, Njuguna P, English M, Were E, Lowe BS, et al. Clinical in-
dicators of bacterial meningitis among neonates and young infants in rural Kenya.
BMC Infect Dis 2011;11:301.
[17] Leung AK, Newman R, Kumar A, Davies HD. Rapid antigen detection testing in
diagnosing group A beta-hemolytic streptococcal pharyngitis. Expert Rev Mol
Diagn 2006;6(5):761-6.
[18] Gathara D, Opiyo N, Wagai J, Ntoburi S, Ayieko P, Opondo C, et al. Quality of hospital
care for sick newborns and severelymalnourished children in Kenya: a two-year de-
scriptive study in 8 hospitals. BMC Health Serv Res 2011;11:307.
[19] Ayieko P, Ntoburi S, Wagai J, Opondo C, Opiyo N, Migiro S, et al. A multifaceted in-
tervention to implement guidelines and improve admission paediatric care in
Kenyan district hospitals: a cluster randomised trial. PLoS Med 2011;8(4):
e1001018.
[20] Conde-Agudelo A, Belizan JM, Diaz-Rossello J. Kangaroo mother care to reduce
morbidity and mortality in low birthweight infants. Cochrane Database Syst Rev
2011(3):CD002771.[21] Urs PS, Khan F, Maiya PP. Bubble CPAP — a primary respiratory support for respi-
ratory distress syndrome in newborns. Indian Pediatr 2009;46(5):409-11.
[22] Gunlemez A, Isken T. Bubble CPAP must be used with care to avoid harm. Arch Dis
Child Fetal Neonatal Ed 2008;93(2):F170-1.
[23] Koyamaibole L, Kado J, Qovu JD, Colquhoun S, Duke T. An evaluation of bubble-CPAP
in a neonatal unit in a developing country: effective respiratory support that can be
applied by nurses. J Trop Pediatr 2006;52(4):249-53.
[24] van den Heuvel M, Blencowe H, Mittermayer K, Rylance S, Couperus A, Heikens
GT, et al. Introduction of bubble CPAP in a teaching hospital in Malawi. Ann
Trop Paediatr 2011;31(1):59-65.
[25] Edmond KM, Kortsalioudaki C, Scott S, Schra SJ, Zaidi AK, Cousens S, et al. Group B
streptococcal disease in infants aged younger than 3 months: systematic review and
meta-analysis. Lancet 2012;379(9815):547-56.
[26] Furyk JS, Swann O, Molyneux E. Systematic review: neonatal meningitis in the
developing world. Trop Med Int Health 2011;16(6):672-9.
[27] Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, et al. Bacter-
emia among children admitted to a rural hospital in Kenya. N Engl J Med
2005;352(1):39-47.
[28] Makoka MH, MillerWC, Hoffman IF, Cholera R, Gilligan PH, Kamwendo D, et al. Bac-
terial infections in Lilongwe, Malawi: aetiology and antibiotic resistance. BMC Infect
Dis 2012;12:67.
[29] Aiken AM, Mturi N, Njuguna P, Mohammed S, Berkley JA, Mwangi I, et al. Risk and
causes of paediatric hospital-acquired bacteraemia in Kiliﬁ District Hospital, Kenya:
a prospective cohort study. Lancet 2011;378(9808):2021-7.
[30] Bang AT, Bang RA, Baitule SB, Reddy MH, Deshmukh MD. Effect of home-based
neonatal care and management of sepsis on neonatal mortality: ﬁeld trial in
rural India. Lancet 1999;354(9194):1955-61.
[31] ClinicalTrials.gov. Safety and immunogenicity of a group b streptococcus vaccine
in non pregnant and pregnant women 18–40 years of age, 2010. Available online
http://clinicaltrials.gov/ct2/show/NCT01193920. Accessed 26.08.2012.
[32] Seib KL, Zhao X, Rappuoli R. Developing vaccines in the era of genomics: a decade
of reverse vaccinology. Clin Microbiol Infect 2012;19(Suppl. 5):1-8.
[33] Sooﬁ S, Cousens S, Imdad A, Bhutto N, Ali N, Bhutta ZA. Topical application of chlor-
hexidine to neonatal umbilical cords for prevention of omphalitis and neonatal
mortality in a rural district of Pakistan: a community-based, cluster-randomised
trial. Lancet 2012;379(9820):1029-36.
[34] Darmstadt GL, Saha SK, Ahmed AS, Ahmed S, Chowdhury MA, Law PA, et al. Effect of
skin barrier therapy on neonatal mortality rates in preterm infants in Bangladesh: a
randomized, controlled, clinical trial. Pediatrics 2008;121(3):522-9.
